Dorothie Scandy Durosier Mertilus

Dorothie Durosier Mertilus practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dorothie Durosier Mertilus' NPI, 1710416979, was assigned on June 9, 2017. Dorothie Durosier Mertilus holds Florida license ARNP9370705.

Dorothie Durosier Mertilus' primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dorothie Durosier Mertilus' primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dorothie Durosier Mertilus to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dorothie Durosier Mertilus practices, 2 sites in all. Vendor and product names are available with a free account.

Primary care is Dorothie Durosier Mertilus' primary specialty in the NPI Registry, under taxonomy code 363LP2300X. Dorothie Durosier Mertilus is licensed in Florida.

CMS data shows 321 Medicare services from Dorothie Durosier Mertilus across 3 procedure codes in 2024, for 155 Medicare patients. Medicare paid $12,329 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 155 Medicare patients who saw Dorothie Durosier Mertilus in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dorothie Durosier Mertilus' median patient age at 70, with 48% women.

In 2024, Dorothie Durosier Mertilus wrote 242 Medicare Part D claims for 72 patients. 74% of them were for generic drugs. CMS names the drug for 109 of them, across 7 drugs with 11 or more claims each, at $786,305 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dorothie Durosier Mertilus for performance year 2024, reported as part of a group. Dorothie Durosier Mertilus accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dorothie Durosier Mertilus as offering telehealth.

CMS Open Payments shows 3 general payments to Dorothie Durosier Mertilus from 3 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $122.